• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dozens of Pediatric Trials Failed to Properly Report Results, Study Finds

Dozens of Pediatric Trials Failed to Properly Report Results, Study Finds

January 30, 2023

Nearly four dozen pediatric clinical trials involving more than 3,600 children failed to publish their findings on ClinicalTrials.gov or in scientific literature, according to a new analysis by U.K.-based trial transparency advocacy group TranspariMED and other non-U.S. researchers.

The analysis, posted on the preprint publication medRxiv, began in September 2022 and looked at 81 trials that were in violation of FDA reporting requirements, having neglected to upload results to CT.gov within a year of completion.

The researchers concluded that 43 pediatric trials within that group (encompassing 3,627 children) were completely unreported as of December 2022, despite the continued push by the FDA and other regulators for greater reporting compliance and enforcement of requirements.

Once again, transparency watchdogs are calling for the agency to step up its game and hold sponsors truly accountable for failing to be compliant.

“Our findings highlight the urgent need for FDA and the NIH to systematically enforce reporting requirements in order to curb research waste, reduce publication bias, and accelerate medical progress,” wrote Till Bruckner, founder of TranspariMED, and his coauthors.

The analysis was confined to trials exclusively involving patients who could be identified as U.S. children by registry data, meaning it left out trials lacking maximum participant age registry data and trials that aimed to enroll adults and children.

The FDA has been called out for failing to penalize noncompliant sponsors despite having this authority and to date has not issued a single fine. At the same time, it has received praise for its use of noncompliance letters, which have had success in pushing sponsors to share trial findings. It sent its first noncompliance letter in 2021 to Acceleron Pharma and has issued three more since then, according to the agency’s website (CenterWatch Weekly, May 3, 2021).

Access the preprint publication here: https://bit.ly/3WDNuqb.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing